# Laurus Labs Limited (LAURUSLABS)

> LAURUSLABS closed at ₹2,405.50 on 30 Oct 2026, trailing P/E 97.0, market cap ₹1,29,969 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Laurus Labs Limited (NSE: LAURUSLABS) closed at ₹2,405.50 on 30 Oct 2026, +167.3% over one year, against a 52-week range of ₹901.40 – ₹2,405.50.

In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹2,206 cr and net profit of ₹441 cr, a 20.0% net margin; revenue grew 33.4% and profit grew 119.4% year on year.

On four consecutive filed quarters its trailing P/E is 97.0; since 25 Apr 2025 its own P/E has ranged from 59.5 to 169.7 (median 96.2), and today's reading is higher than 51% of those 374 trading days.

From the balance sheet dated 30 Sept 2026: return on equity 29.1%, ROCE 33.7%, debt-to-equity 0.41, Piotroski F-score 7 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 73% of 63 sector peers; PBT margin higher than 78% of 63 sector peers; ROE higher than 94% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹2,405.50 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | +18.7% / +116.0% / +167.3% |
| 52-week low – high | ₹901.40 – ₹2,405.50 |
| Market capitalisation | ₹1,29,969 cr |
| Trailing P/E | 97.0 |
| Price / book | 21.45 |
| EV / EBITDA | 54.7 |
| Earnings yield | 1.0% |
| TTM EPS | ₹24.80 |
| TTM net profit | ₹1,340 cr |
| Quarter revenue | ₹2,206 cr |
| Quarter net profit | ₹441 cr |
| Net margin | 20.0% |
| Revenue growth (YoY) | +33.4% |
| Profit growth (YoY) | +119.4% |
| Return on equity | 29.1% |
| ROCE | 33.7% |
| Debt / equity | 0.41 |
| Current ratio | 1.31 |
| Free cash flow | ₹-59 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹294.3 cr |

## Questions

### What is the P/E ratio of Laurus Labs Limited?

Laurus Labs Limited's trailing P/E is 97.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 25 Apr 2025 its P/E has ranged 59.5–169.7.

### What were Laurus Labs Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Laurus Labs Limited reported revenue of ₹2,206 cr and net profit of ₹441 cr (consolidated), filed with the exchange on 29 Oct 2026.

### What is Laurus Labs Limited's ROE?

Return on equity is 29.1% based on the balance sheet dated 30 Sept 2026.

### Does Laurus Labs Limited have debt?

Debt-to-equity is 0.41 on the balance sheet dated 30 Sept 2026.

### What is LAURUSLABS's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, LAURUSLABS traded between ₹901.40 and ₹2,405.50.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/LAURUSLABS

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._